Evaluation and Management of an Elevated PTH Level (204 pg/mL)

Initial Diagnostic Workup

• Simultaneous measurement of corrected serum calcium, renal function (creatinine/eGFR), 25‑hydroxyvitamin D, serum phosphate, and urinary calcium excretion is required to distinguish primary, secondary, or tertiary hyperparathyroidism. 1
• Corrected serum calcium that is elevated or high‑normal together with a PTH of 204 pg/mL confirms primary hyperparathyroidism. 2
• An eGFR < 60 mL/min/1.73 m² indicates secondary hyperparathyroidism due to chronic kidney disease. 1
• Vitamin D deficiency is defined as 25‑hydroxyvitamin D < 20 ng/mL; deficiency is the most common cause of secondary hyperparathyroidism and must be excluded. 3
• Low‑normal serum phosphate supports primary hyperparathyroidism, whereas elevated phosphate suggests CKD‑related secondary hyperparathyroidism. 4
• A 24‑hour urine calcium collection or spot urine calcium/creatinine ratio helps assess calcium excretion and rule out familial hypocalciuric hypercalcemia. 3

Interpretation Based on Calcium and Kidney Function

Primary Hyperparathyroidism (Calcium > 10.2 mg/dL, Normal Renal Function)

• This scenario mandates surgical evaluation. 2
• The PTH level is inappropriately high because hypercalcemia should suppress PTH secretion. 5
• Immediate referral to endocrinology and an experienced parathyroid surgeon is recommended. 2
• Absolute surgical indications include: corrected calcium > 1 mg/dL above the laboratory upper limit, age < 50 years, eGFR < 60 mL/min/1.73 m², osteoporosis (T‑score ≤ ‑2.5), nephrolithiasis, or hypercalciuria > 300 mg/24 h. 2
• Pre‑operative localization with neck ultrasound and/or 99mTc‑sestamibi SPECT/CT should be performed only after biochemical confirmation. 2

Normocalcemic Primary Hyperparathyroidism

• After exclusion of secondary causes (vitamin D deficiency, low dietary calcium, offending medications, malabsorption), persistent PTH elevation with normal calcium carries similar risks of bone loss and kidney stones as overt hypercalcemia. 3
• Referral to endocrinology is advised; surgical candidacy depends on complications such as osteoporosis or nephrolithiasis. 3

Secondary/Tertiary Hyperparathyroidism in Chronic Kidney Disease

CKD Stage 3 (eGFR 30–59 mL/min/1.73 m²)

• Normal or low calcium with PTH = 204 pg/mL denotes secondary hyperparathyroidism requiring medical management. 4
• Target PTH: 2–9 × the assay’s upper normal limit (≈ 70–110 pg/mL for Stage 3). 4
• Initial therapy: dietary phosphate restriction, non‑calcium phosphate binders (if calcium > 10.2 mg/dL), correction of vitamin D deficiency, and adequate calcium intake. 4
• If PTH remains > 110 pg/mL despite these measures, add calcitriol or vitamin D analogs (doxercalciferol, paricalcitol). 4

CKD Stage 4–5 (eGFR < 30 mL/min/1.73 m² or dialysis)

• Target PTH: 2–9 × upper normal limit (≈ 150–300 pg/mL for dialysis patients). 4
• A PTH of 204 pg/mL may be appropriate for this stage; treatment decisions should be guided by calcium and phosphate levels. 4
• If hypercalcemia develops (tertiary hyperparathyroidism) and is refractory to medical therapy, parathyroidectomy should be considered. 2

Dialysis Patients with Severe Hyperparathyroidism

• Persistent PTH > 800 pg/mL with hypercalcemia/hyperphosphatemia despite maximal medical therapy warrants parathyroidectomy. 2
• Total parathyroidectomy offers lower recurrence rates but carries a higher risk of permanent hypoparathyroidism compared with subtotal parathyroidectomy. 2

Critical Pitfalls

• Do not order parathyroid imaging before confirming the biochemical diagnosis; imaging is reserved for surgical planning. 3
• Do not supplement vitamin D when calcium > 10.2 mg/dL; discontinue vitamin D to avoid worsening hypercalcemia. 3
• Elevated PTH in CKD should not be assumed benign; concurrent hypercalcemia indicates tertiary hyperparathyroidism that may require surgery. 5
• PTH assay results can vary up to 47 % between generations and laboratories; always use assay‑specific reference ranges and the same assay for serial monitoring. 1
• Use EDTA plasma (instead of serum) for PTH measurement; it remains more stable at 4 °C. 1
• Biological variation of PTH is ≈ 20 %; serial values must differ by > 54 % to be clinically significant. 3
• PTH exhibits a circadian rhythm and higher concentrations in central blood; obtain fasting morning samples for consistency. 1

Monitoring Strategies

Primary Hyperparathyroidism (Awaiting Surgery)

• Check serum calcium every 3 months. 3
• Ensure adequate hydration and avoid thiazide diuretics. 3
• Maintain calcium intake of 1000–1200 mg/day; avoid excessive restriction or supplementation. 3

Secondary Hyperparathyroidism on Medical Therapy

• Monitor calcium and phosphorus every 2 weeks for the first month after initiating or adjusting vitamin D therapy, then monthly. 2
• Measure PTH monthly for at least 3 months; once target levels are achieved, extend to every 3 months. 2
• Discontinue vitamin D immediately if calcium exceeds 10.2 mg/dL. 3